Melius Pharma
- Biotech or pharma, therapeutic R&D
Swedish, private, clinical-stage drug biopharmaceutical company developing ME-015 (suplatast tosilate) as a safe, effective and well-tolerated oral treatment for chronic cough in patients with idiopathic pulmonary fibrosis (IPF cough). ME-015 is a small molecule immunomodulator with comprehensive clinical and real-world experience confirming good safety and low side effects.
We are currently completing our Phase 2a RCT COSMIC-IPF (clinicaltrials.gov ID NCT05983471) evaluating blinded ME-015 versus placebo for the treatment of IPF cough. IPF diagnosis is externally adjudicated and patients continue to receive standard of care antifibrotic therapy during the study. The study uses the industry-standard objective cough measurement device VitaloJak to assess the effect on cough frequency. Secondary patient and investigator-reported endpoints are assessed to capture the burden and severity of coughing in line with FDA expectations.
Topline results are expected in early Q3/2025.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}